Pathology of androgen deprivation therapy in prostate carcinoma: A comparative study of 173 patients

Francisco Civantos, M. A. Marcial, E. R. Banks, C. K. Ho, V. O. Speights, P. A. Drew, W. M. Murphy, M. S. Soloway

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Background. Leuprolide, an agonist of luteinizing hormone-releasing hormone (LH-RH), and flutamide, an antiandrogen, increasingly are being used in the treatment of clinically localized prostate cancer. Only two small series (of 23 and 12 patients) have been published on the distinctive pathologic changes induced in the prostate by androgen deprivation therapy with discrepancies on the presence of squamous metaplasia, necrosis, and possible tumor destruction by combined androgen deprivation therapy. Methods. One hundred and thirteen radical prostatectomy specimens obtained after at least 3 months of leuprolide-flutamide androgen inhibition therapy and 60 nonhormonally treated prostates in randomly selected clinical Stage T2 prostate adenocarcinoma patients were entirely sectioned. Distinctive histologic findings were tabulated and their statistical value determined. Results. Resection margins of excision were involved by tumor in 43% of untreated and in 19% of androgen-deprived patients. Characteristic changes in androgen-inhibited nontumor glands included atrophy, basal cell prominence, vacuolated luminal cell layer, and squamous and transitional cell metaplasia. Prostatic intraepithelial neoplasia (PIN) was observed in 35% of treated patients. The presence of small tumor glands separated by stroma was the most frequently noted effect of androgen deprivation on prostate adenocarcinoma; pyknosis and branching empty spaces were less frequent. Large clear tumor cells within an inflammatory response was a third histologic pattern. Apparently unaltered tumor areas were observed in 43% of prostates exposed to androgen deprivation therapy. Conclusions. Androgen deprivation therapy results in histologically distinctive changes that can be recognized in both nonneoplastic and neoplastic prostate tissue. Residual tumor was present in all 113 treated radical prostatectomy specimens. In addition to glandular shrinkage, therapy was associated with statistically significant reductions in the frequency of high grade PIN and extension of cancer to prostate specimen margins of excisions.

Original languageEnglish
Pages (from-to)1634-1641
Number of pages8
JournalCancer
Volume75
Issue number7
DOIs
StatePublished - Apr 6 1995

Fingerprint

Androgens
Prostate
Pathology
Carcinoma
Prostatic Intraepithelial Neoplasia
Leuprolide
Flutamide
Metaplasia
Therapeutics
Neoplasms
Prostatectomy
Prostatic Neoplasms
Adenocarcinoma
Androgen Antagonists
Residual Neoplasm
Gonadotropin-Releasing Hormone
Atrophy
Necrosis
Epithelial Cells
Margins of Excision

Keywords

  • androgen deprivation
  • leuprolide
  • luteinizing hormone-releasing hormone effect
  • prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pathology of androgen deprivation therapy in prostate carcinoma : A comparative study of 173 patients. / Civantos, Francisco; Marcial, M. A.; Banks, E. R.; Ho, C. K.; Speights, V. O.; Drew, P. A.; Murphy, W. M.; Soloway, M. S.

In: Cancer, Vol. 75, No. 7, 06.04.1995, p. 1634-1641.

Research output: Contribution to journalArticle

Civantos, Francisco ; Marcial, M. A. ; Banks, E. R. ; Ho, C. K. ; Speights, V. O. ; Drew, P. A. ; Murphy, W. M. ; Soloway, M. S. / Pathology of androgen deprivation therapy in prostate carcinoma : A comparative study of 173 patients. In: Cancer. 1995 ; Vol. 75, No. 7. pp. 1634-1641.
@article{c2a40ce76ba14c0bb2ceb8727b58702c,
title = "Pathology of androgen deprivation therapy in prostate carcinoma: A comparative study of 173 patients",
abstract = "Background. Leuprolide, an agonist of luteinizing hormone-releasing hormone (LH-RH), and flutamide, an antiandrogen, increasingly are being used in the treatment of clinically localized prostate cancer. Only two small series (of 23 and 12 patients) have been published on the distinctive pathologic changes induced in the prostate by androgen deprivation therapy with discrepancies on the presence of squamous metaplasia, necrosis, and possible tumor destruction by combined androgen deprivation therapy. Methods. One hundred and thirteen radical prostatectomy specimens obtained after at least 3 months of leuprolide-flutamide androgen inhibition therapy and 60 nonhormonally treated prostates in randomly selected clinical Stage T2 prostate adenocarcinoma patients were entirely sectioned. Distinctive histologic findings were tabulated and their statistical value determined. Results. Resection margins of excision were involved by tumor in 43{\%} of untreated and in 19{\%} of androgen-deprived patients. Characteristic changes in androgen-inhibited nontumor glands included atrophy, basal cell prominence, vacuolated luminal cell layer, and squamous and transitional cell metaplasia. Prostatic intraepithelial neoplasia (PIN) was observed in 35{\%} of treated patients. The presence of small tumor glands separated by stroma was the most frequently noted effect of androgen deprivation on prostate adenocarcinoma; pyknosis and branching empty spaces were less frequent. Large clear tumor cells within an inflammatory response was a third histologic pattern. Apparently unaltered tumor areas were observed in 43{\%} of prostates exposed to androgen deprivation therapy. Conclusions. Androgen deprivation therapy results in histologically distinctive changes that can be recognized in both nonneoplastic and neoplastic prostate tissue. Residual tumor was present in all 113 treated radical prostatectomy specimens. In addition to glandular shrinkage, therapy was associated with statistically significant reductions in the frequency of high grade PIN and extension of cancer to prostate specimen margins of excisions.",
keywords = "androgen deprivation, leuprolide, luteinizing hormone-releasing hormone effect, prostate cancer",
author = "Francisco Civantos and Marcial, {M. A.} and Banks, {E. R.} and Ho, {C. K.} and Speights, {V. O.} and Drew, {P. A.} and Murphy, {W. M.} and Soloway, {M. S.}",
year = "1995",
month = "4",
day = "6",
doi = "10.1002/1097-0142(19950401)75:7<1634::AID-CNCR2820750713>3.0.CO;2-#",
language = "English",
volume = "75",
pages = "1634--1641",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Pathology of androgen deprivation therapy in prostate carcinoma

T2 - A comparative study of 173 patients

AU - Civantos, Francisco

AU - Marcial, M. A.

AU - Banks, E. R.

AU - Ho, C. K.

AU - Speights, V. O.

AU - Drew, P. A.

AU - Murphy, W. M.

AU - Soloway, M. S.

PY - 1995/4/6

Y1 - 1995/4/6

N2 - Background. Leuprolide, an agonist of luteinizing hormone-releasing hormone (LH-RH), and flutamide, an antiandrogen, increasingly are being used in the treatment of clinically localized prostate cancer. Only two small series (of 23 and 12 patients) have been published on the distinctive pathologic changes induced in the prostate by androgen deprivation therapy with discrepancies on the presence of squamous metaplasia, necrosis, and possible tumor destruction by combined androgen deprivation therapy. Methods. One hundred and thirteen radical prostatectomy specimens obtained after at least 3 months of leuprolide-flutamide androgen inhibition therapy and 60 nonhormonally treated prostates in randomly selected clinical Stage T2 prostate adenocarcinoma patients were entirely sectioned. Distinctive histologic findings were tabulated and their statistical value determined. Results. Resection margins of excision were involved by tumor in 43% of untreated and in 19% of androgen-deprived patients. Characteristic changes in androgen-inhibited nontumor glands included atrophy, basal cell prominence, vacuolated luminal cell layer, and squamous and transitional cell metaplasia. Prostatic intraepithelial neoplasia (PIN) was observed in 35% of treated patients. The presence of small tumor glands separated by stroma was the most frequently noted effect of androgen deprivation on prostate adenocarcinoma; pyknosis and branching empty spaces were less frequent. Large clear tumor cells within an inflammatory response was a third histologic pattern. Apparently unaltered tumor areas were observed in 43% of prostates exposed to androgen deprivation therapy. Conclusions. Androgen deprivation therapy results in histologically distinctive changes that can be recognized in both nonneoplastic and neoplastic prostate tissue. Residual tumor was present in all 113 treated radical prostatectomy specimens. In addition to glandular shrinkage, therapy was associated with statistically significant reductions in the frequency of high grade PIN and extension of cancer to prostate specimen margins of excisions.

AB - Background. Leuprolide, an agonist of luteinizing hormone-releasing hormone (LH-RH), and flutamide, an antiandrogen, increasingly are being used in the treatment of clinically localized prostate cancer. Only two small series (of 23 and 12 patients) have been published on the distinctive pathologic changes induced in the prostate by androgen deprivation therapy with discrepancies on the presence of squamous metaplasia, necrosis, and possible tumor destruction by combined androgen deprivation therapy. Methods. One hundred and thirteen radical prostatectomy specimens obtained after at least 3 months of leuprolide-flutamide androgen inhibition therapy and 60 nonhormonally treated prostates in randomly selected clinical Stage T2 prostate adenocarcinoma patients were entirely sectioned. Distinctive histologic findings were tabulated and their statistical value determined. Results. Resection margins of excision were involved by tumor in 43% of untreated and in 19% of androgen-deprived patients. Characteristic changes in androgen-inhibited nontumor glands included atrophy, basal cell prominence, vacuolated luminal cell layer, and squamous and transitional cell metaplasia. Prostatic intraepithelial neoplasia (PIN) was observed in 35% of treated patients. The presence of small tumor glands separated by stroma was the most frequently noted effect of androgen deprivation on prostate adenocarcinoma; pyknosis and branching empty spaces were less frequent. Large clear tumor cells within an inflammatory response was a third histologic pattern. Apparently unaltered tumor areas were observed in 43% of prostates exposed to androgen deprivation therapy. Conclusions. Androgen deprivation therapy results in histologically distinctive changes that can be recognized in both nonneoplastic and neoplastic prostate tissue. Residual tumor was present in all 113 treated radical prostatectomy specimens. In addition to glandular shrinkage, therapy was associated with statistically significant reductions in the frequency of high grade PIN and extension of cancer to prostate specimen margins of excisions.

KW - androgen deprivation

KW - leuprolide

KW - luteinizing hormone-releasing hormone effect

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0028897498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028897498&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19950401)75:7<1634::AID-CNCR2820750713>3.0.CO;2-#

DO - 10.1002/1097-0142(19950401)75:7<1634::AID-CNCR2820750713>3.0.CO;2-#

M3 - Article

C2 - 8826921

AN - SCOPUS:0028897498

VL - 75

SP - 1634

EP - 1641

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -